Talis Biomedical Corporation TLIS
- Market cap
- $46.3M
- P/E
- 0.0×
Follow TLIS
Target Price Range
Analyst price targets
Free account| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | 54.60 | 6.32 | 4.35 |
Analyst estimates 2024–2026 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | 508.50 | 65.10 | 9.75 |
High Price
|
|||
| — | — | — | — | — | 136 | 136 | 262 | 102 | 99 |
Employees
|
|||
| — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | 2 | 4 | 11 | 8 | 5 | 2 |
Revenue
|
|||
| — | — | — | — | 0.00% | 100.00% | 100.00% | 100.00% | (74.38%) | 98.08% |
Gross Margin
|
|||
| — | — | — | — | (21) | (27) | (91) | (192) | (113) | (62) |
EBT
|
|||
| — | — | — | — | (892.76%) | (690.82%) | (833.15%) | (2,343.90%) | (2,348.55%) | (2,905.67%) |
EBT Margin
|
|||
| — | — | — | 0 | (21) | (27) | (91) | (192) | (113) | (62) |
Net Income
|
|||
| — | — | — | — | 1 | 1 | 1 | 2 | 9 | 1 |
Depreciation
|
|||
| — | — | — | — | 0.67 | 77.52 | 77.36 | 5.42 | 2.67 | 1.17 |
Revenue/Sh
|
|||
| — | — | — | — | (6.00) | (536.08) | (642.57) | (127.14) | (63.57) | (34.12) |
Earnings/Sh
|
|||
| — | — | — | — | (5.89) | (474.19) | (615.45) | (113.42) | (55.62) | (29.29) |
Cash Flow/Sh
|
|||
| — | — | — | — | 0.00 | (11.27) | (58.00) | (1.90) | (0.90) | (0.27) |
Capex/Sh
|
|||
| — | — | — | — | (5.89) | (485.46) | (673.44) | (115.31) | (56.52) | (29.56) |
Free CF/Sh
|
|||
| — | — | — | — | 2.16 | (412.09) | (767.83) | 154.84 | 70.39 | 38.03 |
Book Value/Sh
|
|||
| — | — | — | — | 4 | 0 | 0 | 2 | 2 | 2 |
Shares
|
|||
| — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | — | 5.39 | 5.39 | 5.39 | 11.09 | 2.75 | 6.85 |
PS Ratio
|
|||
| — | — | — | — | 0.00 | 0.00 | 0.00 | 0.39 | 0.10 | 0.21 |
PB Ratio
|
|||
| — | — | — | — | (10.44) | (10.44) | (10.44) | (17.29) | (24.31) | (29.11) |
EV/Sales
|
|||
| — | — | — | — | 1.20 | 1.20 | 1.20 | 0.81 | 1.15 | 1.16 |
EV/FCF
|
|||
| — | — | — | — | (21) | (24) | (87) | (171) | (100) | (53) |
Op' Cash Flow
|
|||
| — | — | — | — | (1) | (1) | (8) | (3) | (2) | 0 |
Capex
|
|||
| — | — | — | — | (21) | (25) | (95) | (174) | (102) | (54) |
FCF
|
|||
| — | — | — | — | 6 | 20 | 173 | 217 | 121 | 69 |
Working Cap'
|
|||
| — | — | — | — | — | — | 1 | 14 | 34 | — |
Total Debt
|
|||
| — | — | — | — | (7) | (22) | (173) | (233) | (130) | (77) |
Net Debt
|
|||
| — | — | — | — | 8 | (21) | (109) | 234 | 127 | 69 |
Sh' Equity
|
|||
| — | — | — | — | (375.06%) | 142.18% | (81.32%) | (82.73%) | (51.95%) | (46.98%) |
ROA
|
|||
| — | — | — | — | 0.00% | 0.00% | 0.00% | (8,371.86%) | 0.00% | 0.00% |
ROIC
|
|||
| — | — | — | — | 58.34% | (72.14%) | 140.51% | (306.27%) | (62.66%) | (63.32%) |
ROE
|
|||
Talis Biomedical Corporation peers in Medical Devices
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| SRTS Sensus Healthcare, Inc. | $47.9M | 0.0× | Compare |
| SNWV Sanuwave Health Inc. | $41.7M | 3.0× | Compare |
| XTNT Xtant Medical Holdings, Inc. | $52.9M | 0.0× | Compare |
| MDAI Spectral AI, Inc. | $53.1M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| NNOX Nano-X Imaging Ltd. | $53.4M | 0.0× | Compare |
| COCH Envoy Medical, Inc. | $55.4M | 0.0× | Compare |
| RPID Rapid Micro Biosystems, Inc. | $55.7M | 0.0× | Compare |
| TELA TELA Bio, Inc. | $57.3M | 0.0× | Compare |
Talis Biomedical Corporation (TLIS) key facts
- Talis Biomedical Corporation (TLIS) is a Medical Devices company in the Healthcare sector.
- Talis Biomedical Corporation’s revenue for fiscal 2023 (year ended December 2023) was $2.1 million, down 55.7% from fiscal 2022.
- As of April 1, 2026, TLIS traded at $2.84, a market capitalization of $46.3 million.
- Return on equity was −63.3% and debt-to-equity 0.00.
Talis Biomedical Corporation (TLIS) Latest News
14 Nov
Talis Biomedical explores strategic alternatives and implements cost reduction plan to preserve cash. The exploration of strategic alternatives and significant cost reduction measures are likely to have a major impact on Talis Biomedical's future and market performance.
10 Aug
Talis Biomedical reported financial results for Q2 2023, highlighted progress in COVID-19 testing and vaginal infection panel development, and announced key appointments. The article discusses significant progress in key strategic areas and financial improvements that could have a major impact on Talis Biomedical's future trajectory.
3 Aug
Talis Biomedical to report Q2 2023 financial results and business update on August 10, 2023. The announcement of financial results and business update can significantly impact the company's trajectory and investor sentiment.
2 Aug
Talis Biomedical appoints Dr. Andrew Lukowiak as President and CSO. Dr. Lukowiak's extensive experience and leadership role may significantly impact Talis Biomedical's future product development and market positioning.
27 Jul
Talis Biomedical presents new data at IDSOG Annual Meeting supporting development of CT/NG/TV and vaginal infection panels for point-of-care testing. The new data presented at the IDSOG Annual Meeting could significantly impact Talis Biomedical's future product development and market positioning.
5 Jul
Talis Biomedical announces 1-for-15 reverse stock split. The reverse stock split will have a moderately noticeable influence on the company's financial performance and market positioning.
23 May
Talis Biomedical appoints Heiner Dreismann to board of directors and Kim Popovits as lead independent director. Appointment of experienced industry leaders to key positions can significantly impact company's strategic direction and market positioning.
11 May
Talis Biomedical announces business update and first quarter 2023 financial results. The financial results and business update may moderately influence key areas like financial performance and competitive positioning.
4 May
Talis Biomedical to provide business update and financial results on May 11, 2023. The financial results and business update may moderately influence key areas like financial performance and competitive positioning.